The stock may react positively to the strong revenue growth and improved profitability, but investors should monitor the expected moderating growth in 2026 and await key clinical data readouts in H2 2026 for brenetafusp and HIV programs.
IMCR drugs
IMCR drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $32.16entry
- T+1 · 9mo ago −0.37%α +0.17% · $32.04
- T+5 · 9mo ago +4.88%α +5.98% · $33.73
- T+20 · 8mo ago −5.85%α −0.61% · $30.28
- T+60 · 6mo ago −8.15%α −15.10% · $29.54
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Immunocore reported strong financial results for Q4 and full year 2025, with KIMMTRAK net sales of $104.5 million and $400.0 million respectively, representing 24% and 29% year-over-year growth. The company reduced its net loss from $51.1 million in 2024 to $35.5 million in 2025 despite increased R&D spending, and ended the year with $864.2 million in cash. Management expects moderating revenue growth in 2026 as it awaits key clinical data readouts.
Key Financial Metrics
Key Facts
- KIMMTRAK net sales were $104.5 million in Q4 2025 (up 24% YoY) and $400.0 million for full year 2025 (up 29% YoY)
- Net loss improved to $35.5 million in 2025 from $51.1 million in 2024 despite higher R&D expenses
- Cash, cash equivalents and marketable securities totaled $864.2 million as of December 31, 2025
- R&D expenses increased to $274.9 million in 2025 from $222.2 million in 2024 due to autoimmune programs and Phase 3 trials
- Company expects moderating revenue growth in 2026 and anticipates key data readouts in second half of 2026
Financial Impact
$400 million in annual revenue with improving profitability and strong cash position
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| KIMMTRAK | $400.0M | +29.0% |
Risk Factors
- Management expects moderating revenue growth in 2026
- Key clinical data readouts in H2 2026 could impact the stock positively or negatively
- Increased R&D spending could pressure margins if not offset by revenue growth
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001140361-26-006721 |
| Document: ef20066378_8k.htm | 0001140361-26-006721 |
| Document: 0001140361-26-006721-index-headers.html | 0001140361-26-006721 |
| Document: 0001140361-26-006721-index.html | 0001140361-26-006721 |
| Document: 0001140361-26-006721.txt | 0001140361-26-006721 |
Track record
14 reports on IMCR
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 9, 20267d ago SC 13G Neutral 4/10 Entry $32.38 Now $28.88 −10.81% settles Feb 8
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $30.99 Now $28.88 −6.81% settles Feb 4
- Nov 6, 202610d ago 8-K Neutral 4/10 No price data
- Nov 6, 202610d ago Press Release Bearish 5/10 Entry $30.99 Now $28.88 +6.81% settles Feb 4
- Oct 29, 202618d ago Press Release Neutral 3/10 Entry $31.27 Now $28.88 −7.64% settles Jan 27
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $29.48 Now $28.88 −2.04% settles Jan 12
- Oct 7, 20265w ago SC 13G/A Neutral 3/10 Entry $29.41 Now $28.88 −1.80% settles Jan 4
- Sep 14, 20269w ago 8-K Bullish 6/10 Entry $32.46 Now $28.88 −11.03% settles Dec 8
- Aug 6, 202614w ago 8-K Mixed 5/10 Entry $34.50 to $30.49 Now $28.88 −16.29% ▼ −11.62% −9.95% vs SPY
- May 31, 202624w ago Press Release Bullish 6/10 Entry $29.13 to $37.40 Now $28.88 −0.86% ▲ +28.39% +27.16% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers